{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.ifenprodil","code":"thing-q5991156","url":"https://ver.cy/models/thing/q5991156/","name":"ifenprodil","alternateNames":["4-[(1R,2S)-2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol"],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Physical world and living systems","entryKind":"thing","plane":"PHY","domain":["PHY.MAT"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Ifenprodil is a synthetic small-molecule vasodilator and noncompetitive antagonist of GluN2B-containing NMDA receptors, used pharmacologically and as a research tool.","purpose":"Enable an agent to recognise ifenprodil, evaluate the identity and condition of a supplied material, and determine whether its documented properties support a proposed use.","scope":{"in":["Ifenprodil molecular identity and externally verified identifiers","Stereochemical composition and relationships between free base and supplied salts","Batch purity, impurities, analytical identity and provenance","Physical state, solubility, stability and concentration basis","Assay-specific biological activity and substance-level handling constraints"],"out":["Finished medicines, packaging and excipient formulations","Patient-specific prescribing, dosing and treatment decisions","Manufacturing processes and synthesis routes","NMDA receptors and other biological targets as independently modelled entities","Clinical trials, diseases and therapeutic efficacy assessments"],"boundaries":[]},"distinguishingFeatures":["Match molecular connectivity to 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol rather than accepting a shared pharmacological label as identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Ifenprodil)","Cross-check the parent record against formula C21H27NO2, CAS 23210-56-2 and PubChem CID 3689; a formula match alone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Ifenprodil)","Require explicit stereochemical evidence before treating a stereospecified material as equivalent to the parent record, whose displayed InChIKey does not specify stereochemistry. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Ifenprodil)","Distinguish parent ifenprodil from ifenprodil tartrate by counterion and stoichiometry; PubChem maintains a separate tartrate record. [PubChem: Ifenprodil Tartrate](https://pubchem.ncbi.nlm.nih.gov/compound/Ifenprodil-Tartrate)","Do not identify a material solely through an NMDA-related response: experimental work also reports presynaptic P/Q-type calcium-channel effects. [Primary study](https://pubmed.ncbi.nlm.nih.gov/22205650/)"],"structure":{"bundles":[{"id":"ifenprodil-identity","name":"Ifenprodil identity","description":"Establishes which chemical entity a record or material represents.","layers":[{"id":"parent-structure","name":"Parent structure","description":"Connects the registry entry to verified molecular connectivity and identifiers.","findings":[{"id":"identity-concordance","name":"Identity concordance","description":"Require agreement between structure and identifiers before accepting an ifenprodil identity.","questions":[{"text":"Does the supplied structure match the parent ifenprodil connectivity associated with PubChem CID 3689?","id":"identity-concordance-q01","kind":"definition"},{"text":"Which inspected source establishes each identifier, and does it identify the parent or a particular salt or stereoisomer?","id":"identity-concordance-q02","kind":"provenance"}]}]},{"id":"stereochemical-boundary","name":"Stereochemical boundary","description":"Separates the parent name from claims about the stereochemistry of actual material.","findings":[{"id":"isomer-specification","name":"Isomer specification","description":"Record specified configurations and mixture composition without inferring them from an unspecific identifier.","questions":[{"text":"What configurations or stereoisomer mixture does this ifenprodil material claim to contain?","id":"isomer-specification-q01","kind":"definition"},{"text":"What analytical evidence establishes its enantiomeric and diastereomeric composition?","id":"isomer-specification-q02","kind":"measurement"}]}]}]},{"id":"ifenprodil-material-basis","name":"Ifenprodil material basis","description":"Describes how the parent substance is represented in a supplied solid or solution.","layers":[{"id":"salt-stoichiometry","name":"Salt stoichiometry","description":"Establishes the relationship between ifenprodil and any counterion or bound solvent.","findings":[{"id":"supplied-form","name":"Supplied form","description":"Treat a salt designation as a relationship requiring a verified formula and ratio.","questions":[{"text":"Is the material free-base ifenprodil or a salt, and what counterion-to-ifenprodil ratio is established?","id":"supplied-form-q01","kind":"definition"},{"text":"Does its certificate identify water or solvent contributions that change the mass basis?","id":"supplied-form-q02","kind":"provenance"}]}]},{"id":"parent-equivalent-accounting","name":"Parent-equivalent accounting","description":"Makes conversions from weighed material to ifenprodil amount traceable.","findings":[{"id":"concentration-basis","name":"Concentration basis","description":"Require the reported concentration to identify the chemical entity and correction factors used.","questions":[{"text":"Is the reported concentration based on salt formula units, total supplied mass or moles of ifenprodil parent?","id":"concentration-basis-q01","kind":"measurement"},{"text":"Are stoichiometry, molecular mass, water content and assay content sufficiently established to calculate parent-equivalent concentration?","id":"concentration-basis-q02","kind":"action"}]}]}]},{"id":"ifenprodil-quality-and-condition","name":"Ifenprodil quality and condition","description":"Evaluates analytical quality and the state of an ifenprodil batch or preparation.","layers":[{"id":"batch-characterisation","name":"Batch characterisation","description":"Connects identity and quality claims to the actual lot.","findings":[{"id":"analytical-acceptance","name":"Analytical acceptance","description":"Keep structural confirmation, quantitative content and impurity evidence distinct.","questions":[{"text":"Which lot-specific analytical results confirm ifenprodil identity and distinguish relevant isomeric or chemical impurities?","id":"analytical-acceptance-q01","kind":"provenance"},{"text":"What are the measured content, chromatographic purity and residual solvent or water levels, with methods and reporting bases?","id":"analytical-acceptance-q02","kind":"measurement"}]}]},{"id":"preparation-state","name":"Preparation state","description":"Tracks the conditions under which solid material and stock solutions remain characterised.","findings":[{"id":"solubility-and-stability","name":"Solubility and stability","description":"Attach physical-property and stability claims to the supplied form and preparation conditions.","questions":[{"text":"What measured solubility and thermal data apply to this ifenprodil form, with solvent, pH, temperature and method specified?","id":"solubility-and-stability-q01","kind":"measurement"},{"text":"Do storage history, solution age, precipitation or analytical changes require remeasurement before using the stated concentration?","id":"solubility-and-stability-q02","kind":"action"}]}]}]},{"id":"ifenprodil-activity-interpretation","name":"Ifenprodil activity interpretation","description":"Links characterised ifenprodil material to evidence for receptor and cellular effects.","layers":[{"id":"nmda-assay-context","name":"NMDA assay context","description":"Structures the evidence needed to interpret GluN2B-related activity claims.","findings":[{"id":"subunit-dependent-evidence","name":"Subunit-dependent evidence","description":"Require explicit receptor composition and assay conditions when evaluating claimed inhibition.","questions":[{"text":"Which experiment establishes the claimed ifenprodil effect, and what species and GluN1/GluN2 subunit composition were tested?","id":"subunit-dependent-evidence-q01","kind":"provenance"},{"text":"What endpoint, potency, concentration basis, pH and exposure conditions were measured?","id":"subunit-dependent-evidence-q02","kind":"measurement"}]}]},{"id":"alternative-effect-attribution","name":"Alternative effect attribution","description":"Tests whether an observed response supports the proposed target attribution.","findings":[{"id":"selectivity-limits","name":"Selectivity limits","description":"Record alternative pharmacological explanations and the controls needed to distinguish them.","questions":[{"text":"What evidence addresses non-NMDA effects, including the reported P/Q-type calcium-channel effect, at the tested concentration?","id":"selectivity-limits-q01","kind":"boundary"},{"text":"Which orthogonal controls are needed before attributing this preparation's observed effect to GluN2B-containing receptors?","id":"selectivity-limits-q02","kind":"action"}]}]}]},{"id":"ifenprodil-handling-and-use","name":"Ifenprodil handling and use","description":"Connects material-specific hazard evidence and applicable status to proposed operations.","layers":[{"id":"form-specific-hazards","name":"Form-specific hazards","description":"Associates handling decisions with evidence for the supplied chemical form and preparation.","findings":[{"id":"hazard-evidence","name":"Hazard evidence","description":"Keep verified classifications and exposure limits separate from absent or unresolved information.","questions":[{"text":"Which current safety data sheet or authoritative assessment covers this ifenprodil form and concentration?","id":"hazard-evidence-q01","kind":"provenance"},{"text":"What hazard classification, exposure limits and handling or disposal requirements does that evidence establish?","id":"hazard-evidence-q02","kind":"action"}]}]},{"id":"use-status-boundary","name":"Use status boundary","description":"Separates substance identification from permission to use a particular material for a particular purpose.","findings":[{"id":"documented-use-eligibility","name":"Documented use eligibility","description":"Evaluate intended use using dated jurisdictional evidence and the supplied grade.","questions":[{"text":"What jurisdiction, intended use and material grade apply to the proposed operation involving ifenprodil?","id":"documented-use-eligibility-q01","kind":"boundary"},{"text":"Which dated authoritative record establishes applicable restrictions or permissions, and does it concern the substance or a specific medicinal product?","id":"documented-use-eligibility-q02","kind":"provenance"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of ifenprodil this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-kinds","name":"Kinds and varieties","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these kinds and varieties hold for the sense of ifenprodil this model covers, and on what evidence?","id":"evidence-kinds-q01","kind":"provenance"}]},{"id":"evidence-identifiers","name":"Identifiers and schemes","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these identifiers and schemes hold for the sense of ifenprodil this model covers, and on what evidence?","id":"evidence-identifiers-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of ifenprodil this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-measurements","name":"Typical measurements","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these typical measurements hold for the sense of ifenprodil this model covers, and on what evidence?","id":"evidence-measurements-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of ifenprodil this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-regional-variation","name":"Regional variation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these regional variation hold for the sense of ifenprodil this model covers, and on what evidence?","id":"evidence-regional-variation-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of ifenprodil this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Describe ifenprodil, its receptor actions and its uses from official drug information and research sources.","Report the research grade and handling information of a sample from its safety data sheet.","Track stock in a laboratory or pharmacy the agent is authorized to manage."],"mustNot":["Recommend, dose or adjust ifenprodil for a particular person.","Promote it for unapproved uses, such as mood or cognitive effects, without clinical evidence.","Help anyone obtain it without a prescription where one is required.","Present animal or cell research as proof of benefit in people."],"requiresHuman":["Any prescribing or clinical trial decision involving the drug."]},"ethics":{"considerations":["Drugs acting on brain receptors can have serious side effects, so claims must be careful.","Research tools can be misused as unregulated supplements."],"affectedParties":["Patients","Research participants","Laboratory workers"]},"owners":{"steward":"The prescribing clinician or the laboratory that holds it; medicines regulators authorize medical use.","roles":[],"masterSystems":["National medicines registers"]},"relations":[{"target":"Q11173","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.ifenprodil","Wikidata: Q5991156 (https://www.wikidata.org/wiki/Q5991156)"]},"properties":{"applicability":"required","items":["Parent chemical identity: Verified structure, formula, CAS, PubChem CID and EC identifier, each with source and chemical-form scope","Stereochemical specification: Assigned configurations, specified mixture, or unresolved; include supporting method","Salt and solvation relationship: Parent moiety, counterion, molar ratio, hydrate or solvate status, and supporting evidence","Content and purity: Mass fraction or % w/w for content; chromatographic area % recorded separately, with method and reporting basis","Stereoisomer composition: Isomer fractions in %, or validated enantiomeric and diastereomeric ratios","Physical and solution state: Solid form or solution; solvent, pH, temperature, precipitation and water content where relevant","Condition-dependent physical constants: Solubility in mg/mL or mol/L; thermal transitions in °C; pressure for boiling data; measured or predicted status","Ifenprodil concentration: mol/L or mg/mL, explicitly reported as supplied compound or parent-if enprodil equivalent","Biological activity evidence: Material-to-assay link with target composition, species, endpoint, concentration range and source","Handling and regulatory status: Form-specific hazard classification, applicable exposure limits or unknown status, jurisdiction, intended use and verification date"]},"recognition":{"applicability":"required","items":["A container label naming ifenprodil distinguishes its declared contents from other receptor antagonists, although the label does not prove chemical identity.","The label or accompanying material record should distinguish the free base from a named salt because these are different supplied forms.","A white or off-white powder appearance is compatible with supplied ifenprodil materials but cannot distinguish them from many unrelated chemicals."]},"capabilities":{"applicability":"required","items":["Reconcile a supplier label and certificate with the ifenprodil parent identity and the actual supplied chemical form.","Calculate parent-equivalent quantities when salt stoichiometry, solvation and content are established.","Compare batches using chemical identity, stereochemical composition and analytical quality.","Assess whether a stock solution has a supported concentration and remains within documented stability conditions.","Evaluate whether an activity claim applies to the material and assay under consideration.","Flag material for additional analysis or restricted use when identity, condition or applicable handling evidence is missing."]},"hazards":{"applicability":"required","items":["Can lower blood pressure and cause dizziness.","Interactions with other drugs acting on the brain or circulation are possible."]},"interfaces":{"applicability":"required","items":["The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology assigns ifenprodil code C04AX28 within other peripheral vasodilators."]},"context":{"applicability":"required","items":["Ifenprodil is encountered in pharmacological research, particularly studies involving GluN2B-containing NMDA receptors.","It also appears in pharmaceutical contexts associated with its vasodilator activity, where the chemical form and material specification affect suitability."]}},"sources":[{"title":"Wikidata item Q5991156: ifenprodil","url":"https://www.wikidata.org/wiki/Q5991156","note":"identity and sense of the item"},{"title":"Wikipedia: Ifenprodil","url":"https://en.wikipedia.org/wiki/Ifenprodil","note":"general description of the item"}],"openQuestions":["Does the registry intend a particular stereoisomer mixture, or should vr.tr.ifenprodil retain a stereochemically unspecified parent identity?","Which salt stoichiometries and hydrate or solvate forms occur in the materials to be represented, and how should their identifiers link to the parent?","Which measured solubility, thermal and storage-stability values are sufficiently reliable for each relevant chemical form?","What concentration-dependent evidence establishes GluN2B-related activity and alternative target effects for the intended experimental systems?","Which current form-specific hazard classifications, exposure limits and jurisdictional use restrictions can be established from authoritative records?"],"resources":{"spec":"/models/things/publications/thing-q5991156/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q5991156/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T10:24:47Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"filled","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:31+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass"},"score":1.0}}